BARACLUDE Data Show Low Resistance Over 5 Years In Nucleoside-Naive Hepatitis B Patients

New BARACLUDE® (entecavir) data presented 24th March demonstrated a continued low incidence of resistance in nucleoside-naive patients through five years of treatment. In the nucleoside-naive chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108). Through five years of treatment, the cumulative probability of developing mutations in the virus that confer resistance to BARACLUDE (also called genotypic resistance) was 1.2 percent.

More: continued here

Filed under: Liver Disease / Hepatitis on April 2nd, 2008